表紙
市場調查報告書

精密癌症診斷檢驗的全球市場預測:肺癌、乳癌、大腸癌、血液癌症、胃癌 (2019∼2029年)

Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029: Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy

出版商 Visiongain Ltd 商品編碼 904885
出版日期 內容資訊 英文 195 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
精密癌症診斷檢驗的全球市場預測:肺癌、乳癌、大腸癌、血液癌症、胃癌 (2019∼2029年) Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029: Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy
出版日期: 2019年06月06日內容資訊: 英文 195 Pages
簡介

全球精密癌症診斷檢驗的市場規模在2018年估算為39億4,000萬美元,在預測期間中預測將以22.1%的年複合成長率 (CAGR) 擴大。

本報告提供全球精密癌症診斷檢驗市場相關分析,市場概要,主要的推動及阻礙市場要素,各市場區隔、地區/主要國家市場詳細趨勢,及主要企業的簡介等系統性資訊。

第1章 調查概要

第2章 簡介:精準醫學 (精密醫療)

  • 精準醫學的演進和簡歷
  • 精準醫學的主要的優點
  • 精準醫學:主的應用程式領域
  • 精準醫學:主要因素
  • 精準醫學:巨量資料企業使用的各種資料
  • 精準醫學:關心領域

第3章 定性分析

  • 市場動態
    • 促進因素、機會
    • 阻礙因素、課題
  • 法規分析:精密診斷 (搭配診斷)

第4章 精密癌症診斷檢驗市場:各癌症類型

  • 肺癌
  • 乳癌
  • 大腸癌
  • 血液癌症
  • 胃癌
  • 其他

第5章 精密癌症診斷檢驗市場:各切片檢查方法

  • 組織切片檢查
  • 液態生物檢體

第6章 主要國家的精密癌症診斷檢驗市場

  • 美國
  • 日本
  • 德國
  • 法國
  • 義大利
  • 英國
  • 西班牙
  • 中國
  • 印度
  • 巴西
  • 俄羅斯

第7章 主要企業

  • Roche Holding AG
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen, N.V.
  • Abbott Laboratories
  • bioMerieux SA
  • Agilent Technologies, Inc.
  • Siemens Healthineers (A Division of Siemens AG)
  • Myriad Genetics, Inc.
  • Genomic Health, Inc.

第8章 結論

附錄

目錄
Product Code: PHA0437

The global precision cancer diagnostics tests market was estimated at $3.94 bn in 2018 and is expected to grow at a CAGR of 22.1% during the forecast period. The lung cancer submarket held 23% of the global precision cancer diagnostic tests market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 195-page report you will receive 131 tables and 66 figures- all unavailable elsewhere.

The 195-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029
  • Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Cancer Type:
  • Lung Cancer
  • Breast Cancer: HER-2 Positive, HR Positive, TNBC
  • Colorectal Cancer
  • Other Cancers

image1

  • Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Biopsy Type:
  • Tissue Biopsy
  • Liquid Biopsy
  • Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Regional and National market:
  • US
  • Japan
  • Germany
  • France
  • Italy
  • UK
  • Spain
  • China
  • India
  • Brazil
  • Russia

The forecast of each country is further broken down by cancer type and biopsy type.

  • Profile of the selected leading companies:
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Roche Holding AG
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.
  • Analysis of factors that drive and restrain the global precision cancer diagnostics tests market
  • Key Questions Answered by this Report:
  • How the global precision cancer diagnostic tests market is evolving?
  • What are the drivers, restraints and opportunities in the global precision cancer diagnostic tests market?
  • How will each of the sub-markets of the precision cancer diagnostic tests market develop over the period of study?
  • Who are the leading players in the precision cancer diagnostic tests market and what are their future perspective during the period of study?
  • What are the recent developments in the global precision cancer diagnostic tests market?

Table of Contents

1. Report Overview

  • 1.1 Global Precision Cancer Diagnostic Tests Market Overview
  • 1.2 Why You Should Read This Report
  • 1.3 How the Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report Include
  • 1.5 Who is This Report For?
  • 1.6 Methodology
    • 1.6.1 Primary Research
    • 1.6.2 Secondary Research
    • 1.6.3 Market Evaluation & Forecasting Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports

2. Introduction to Precision Medicine

  • 2.1 Evolution and Brief History of Precision Medicine
  • 2.2 Key Benefits of Precision Medicine
  • 2.3 Precision Medicine: Key Application Areas
  • 2.4 Precision Medicine: Key Elements
  • 2.5 Precision Medicine: Different Type of Data Used by Big Data Companies
  • 2.6 Precision Medicine: Area of Interest

3. Qualitative Analysis

  • 3.1 Market Dynamics
    • 3.1.1 Drivers and Opportunities
      • 3.1.1.1 Growing Volume of Precision Cancer Diagnostic Tests Receiving Regulatory Approval
      • 3.1.1.2 Improving Reimbursement Scenario in the Developed Markets
      • 3.1.1.3 Government Support for Precision Medicine
      • 3.1.1.4 Precision Cancer Assays Based on Liquid Biopsies Offer High Growth Opportunities
      • 3.1.1.5 Growing Aging Population and Cancer Prevalence
    • 3.1.2 Restraints and Challenges
      • 3.1.2.1 High Cost of Precision Tests and Therapies
      • 3.1.2.2 Limited Access and Delay in Test Results
  • 3.2 Regulatory Analysis: Precision Diagnostics (Companion Diagnostics)

4. Precision Cancer Diagnostic Tests Market by Cancer Type

  • 4.1 Lung Cancer
  • 4.2 Breast Cancer
    • 4.2.1 HER2 Positive Breast Cancer
    • 4.2.2 Hormone Receptor (HR)-positive Breast Cancer
    • 4.2.3 Triple Negative Breast Cancer
  • 4.3 Colorectal Cancer
  • 4.4 Blood Cancer
  • 4.5 Stomach (Gastric) Cancer
  • 4.6 Other Cancers

5. Precision Cancer Diagnostic Tests Market by Biopsy Method

  • 5.1 Tissue Biopsy
  • 5.2 Liquid Biopsy

6. Leading National Precision Cancer Diagnostic Tests Markets, 2018-2029

  • 6.1 US
  • 6.2 Japan
  • 6.3 Germany
  • 6.4 France
  • 6.6 Italy
  • 6.6 UK
  • 6.7 Spain
  • 6.8 China
  • 6.9 India
  • 6.10 Brazil
  • 6.11 Russia

7. Leading Companies in the Precision Cancer Diagnostic Tests Market

  • 7.1 Roche Holding AG
    • 7.1.1 Roche: Precision Cancer Diagnostics Product Portfolio
    • 7.1.2 Sales and Recent Performance Analysis, 2017
    • 7.1.3 Recent Developments
      • 7.1.3.1 FDA Approval for triple-Negative Breast Cancer Test
      • 7.1.3.2 Collaboration with Phoenix Molecular Designs (PhoenixMD)
      • 7.1.3.3 Partnership with Merck to develop pan-cancer companion diagnostic test
      • 7.1.3.4 Collaboration Agreement with Daiichi Sankyo
      • 7.1.3.5 FDA Approval for cobas EGFR Mutation Test v2 as a companion diagnostic test (CDx) with IRESSA
      • 7.1.3.6 Roche acquires Foundation Medicine
      • 7.1.3.7 Collaboration with Five Prime Therapeutics
      • 7.1.3.8 Extension of Collaboration Agreement with Pierre Fabre
      • 7.1.3.9 FDA Approval for cobas EGFR Mutation Test v2 as a Companion Diagnostic with Tagrisso
      • 7.1.3.10 FDA Approval for Ventana ALK (D5F3) companion diagnostic for Alecensa
      • 7.1.3.11 CE Mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody
      • 7.1.3.12 FDA Approval for VENTANA ALK (D5F3) CDx Assay
      • 7.1.3.13 FDA Approval for cobas EGFR Mutation Test v2
  • 7.2 Illumina, Inc.
    • 7.2.1 Sales and Recent Performance Analysis, 2017
    • 7.2.2 Illumina: Precision Cancer Diagnostics Product Portfolio
    • 7.2.3 Recent Developments
      • 7.2.3.1 Partnership with Loxo Oncology
      • 7.2.3.2 FDA Approval for Praxis Extended RAS Panel
  • 7.3 Thermo Fisher Scientific, Inc.
    • 7.3.1 Sales and Recent Performance Analysis, 2017
    • 7.3.2 Thermo Fisher: Precision Cancer Diagnostics Product Portfolio
    • 7.3.3 Recent Developments
      • 7.3.3.1 Agreement with Daiichi Sankyo and Takeda Pharmaceutical
      • 7.3.3.2 Companion Diagnostic Partnership with Spectrum Pharmaceuticals, Inc.
      • 7.3.3.3 Companion Diagnostic Development Agreement with Blueprint Medicines
      • 7.3.3.4 Companion Diagnostic Partnership with Agios Pharmaceuticals, Inc.
  • 7.4 Qiagen, N.V.
    • 7.4.1 Sales and Recent Performance Analysis, 2018
    • 7.4.2 Qiagen: Precision Cancer Diagnostics Product Portfolio
    • 7.4.3 Recent Developments
      • 7.4.3.1 Collaboration with Novartis
      • 7.4.3.2 Launch of the QIAscreen HPV PCR Test
      • 7.4.3.3 Launch of Innovative Sample to Insight workflows
      • 7.4.3.4 FDA Approval to Expand Use of EGFR Test
      • 7.4.3.5 Collaboration with Japan's clinical laboratory testing company, SRL, Inc.
      • 7.4.3.6 Public-private Alliance in the U.K.
      • 7.4.3.7 Launch of AdnaTest Liquid Biopsy Kits in Prostate and Lung Cancer
      • 7.4.3.8 Partnership with Natera
      • 7.4.3.9 Launch of Predictive therascreen PITX2 Test in Europe
      • 7.4.3.10 FDA Clearance for JAK2 Test
      • 7.4.3.11 FDA Approval to Expand Use of EGFR test in Lung Cancer
      • 7.4.3.12 Partnership with Clinical Genomics
      • 7.4.3.13 Partnership with Bristol-Myers Squibb
      • 7.4.3.14 Commercialisation of the Research Use Only AdnaTest Prostate Cancer Panel AR-V7
      • 7.4.3.15 FDA Clearance of JAK2 Test for Leukemia
  • 7.5 Abbott Laboratories
    • 7.5.1 Abbott: Precision Cancer Diagnostics Product Portfolio
    • 7.5.2 Sales and Recent Performance Analysis, 2017
    • 7.5.3 Recent Developments
      • 7.5.3.1 FDA Approvals
  • 7.6 bioMérieux SA
    • 7.6.1 bioMérieux: Precision Cancer Diagnostics Product Portfolio
    • 7.6.3 Recent Developments
      • 7.7 Agilent Technologies, Inc.
    • 7.7.1 Agilent Technologies: Precision Cancer Diagnostics Product Portfolio
    • 7.7.2 Sales and Recent Performance Analysis, 2018
    • 7.7.3 Recent Developments
      • 7.7.3.1 Expanded FDA Approval for Urothelial Carcinoma
      • 7.7.3.2 Expanded FDA Approval for Cervical Cancer
      • 7.7.3.3 Acquisition of Lasergen, Inc.
      • 7.7.3.4 Expanded FDA Approval for Gastric or Gastroesophageal Junction (GEJ) Cancer
      • 7.7.3.5 Expanded FDA Approval for PD-L1 IHC 28-8 pharmDx
      • 7.7.3.6 Introduction of the AriaDx Real-Time PCR System
      • 7.7.3.7 Agreement with Agendia, Inc.
  • 7.8 Siemens Healthineers (A Division of Siemens AG)
    • 7.8.1 Siemens: Precision Cancer Diagnostics Product Portfolio
    • 7.8.2 Sales and Recent Performance Analysis, 2018
    • 7.8.3 Recent Developments
      • 7.9 Myriad Genetics, Inc.
    • 7.9.1 Myriad Genetics: Precision Cancer Diagnostics Product Portfolio
    • 7.9.2 Sales and Recent Performance Analysis, 2017
    • 7.9.3 Recent Developments
      • 7.9.3.1 Expansion of Companion Diagnostic Partnership
      • 7.9.3.2 Approval of BRACAnalysis CDx for Advanced Ovarian Cancer Therapy- Lynparza
      • 7.9.3.3 Approval of BRACAnalysis CDx for advanced ovarian cancer therapy- TALZENNA
      • 7.9.3.4 Laboratory Agreement with Pfizer
      • 7.9.3.5 Approval of BRACAnalysis CDx for Metastatic Breast Cancer Therapy- Lynparza
      • 7.9.3.6 Expanded Research Collaboration with AstraZeneca
      • 7.9.3.7 Companion Diagnostic Collaboration with Clovis Oncology
      • 7.9.3.8 Companion Diagnostic Collaboration with BeiGene
  • 7.10 Genomic Health, Inc.
    • 7.10.1 Genomic Health: Precision Cancer Diagnostics Product Portfolio
    • 7.10.2 Sales and Recent Performance Analysis, 2017
    • 7.10.3 Recent Developments
      • 7.10.3.1 Expansion of Collaboration with Biocartis
      • 7.10.3.2 Launch of Oncotype DX AR-V7 Nucleus Detect
      • 7.10.3.3 Research Collaboration with Janssen Pharmaceuticals
      • 7.10.3.4 Strategic Collaboration with Cleveland Diagnostics
      • 7.10.3.5 Agreement with Biocartis to Develop an Idylla IVD Oncotype DX Breast Cancer Test

8. Conclusions

  • 8.1 The Precision Cancer Diagnostic Tests Market Will Exhibit Lucrative Growth through 2029
  • 8.2 Lung Cancer is the Largest Submarket
  • 8.3 Liquid Biopsy Based Diagnostic Tests Will Offer Significant Growth Opportunities
  • 8.4 Prominent Companies in the Market
  • 8.5 Leading Regional Markets
  • 8.6 Concluding Remarks

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain

List of Tables

  • Table 2.1 Key Benefits of Precision Medicine
  • Table 2.2 Key Elements of Precision Medicine
  • Table 4.1 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.2 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.3 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029
  • Table 4.4 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.5 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.6 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.7 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.8 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.9 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.10 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029
  • Table 4.11 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.12 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.13 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.14 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.15 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.16 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.17 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.18 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.19 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.20 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.21 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.22 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.23 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.24 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.25 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.26 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 4.27 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 4.28 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 5.1 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 5.2 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 5.3 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029
  • Table 5.4 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 5.5 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 5.6 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
  • Table 5.7 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
  • Table 6.1 Precision Cancer Diagnostic Tests Market: Regional Sales ($m) and Market Shares (%), 2018, 2024 and 2029
  • Table 6.2 Precision Cancer Diagnostic Tests Market: National and Regional Revenue Forecasts ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.3 Precision Cancer Diagnostic Tests Market: National and Regional Revenue Forecasts ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.4 US Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.5 US Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.6 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.7 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.8 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.9 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.10 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.11 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.12 Japanese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.13 Japanese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.14 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.15 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.16 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.17 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.18 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.19 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.20 German Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.21 German Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.22 German Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.23 German Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.24 German Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.25 German Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.26 German Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.27 German Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.28 French Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.29 French Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.30 French Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.31 French Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.32 French Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.33 French Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.34 French Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.35 French Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.36 Italian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.37 Italian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.38 Italian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.39 Italian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.40 Italian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.41 Italian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.42 Italian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.43 Italian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.44 UK Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.45 UK Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.46 UK Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.47 UK Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.48 UK Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.49 UK Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.50 UK Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.51 UK Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.52 Spanish Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.53 Spanish Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.54 Spanish Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.55 Spanish Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.56 Spanish Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.57 Spanish Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.58 Spanish Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.59 Spanish Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.60 Chinese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.61 Chinese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.62 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.63 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.64 Chinese Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.65 Chinese Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.66 Chinese Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.67 Chinese Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.68 Indian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.69 Indian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.70 Indian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.71 Indian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.72 Indian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.73 Indian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.74 Indian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.75 Indian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.76 Brazilian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.77 Brazilian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.78 Brazilian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.79 Brazilian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.80 Brazilian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.81 Brazilian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.82 Brazilian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.83 Brazilian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.84 Russian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.85 Russian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.86 Russian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.87 Russian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.88 Russian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.89 Russian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 6.90 Russian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
  • Table 6.91 Russian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
  • Table 8.1 Precision Cancer Diagnostic Tests Market: Submarket (Cancer Type) Forecasts ($m) and Market Shares (%), 2018, 2024 and 2029
  • Table 8.2 Precision Cancer Diagnostic Tests Market: Submarket (Biopsy type) Forecasts ($m) and Market Shares (%), 2018, 2024 and 2029
  • Table 8.3 Precision Cancer Diagnostic Tests National Market: Revenue Forecasts ($m) and Market Shares (%), 2018, 2024, and 2029

List of Figures

  • Figure 1.1 Global Precision Cancer Diagnostic Tests Market - Segmentation by Cancer Type
  • Figure 1.2 Global Precision Cancer Diagnostic Tests Market - Segmentation by Biopsy Method
  • Figure 1.3 Global Precision Cancer Diagnostic Tests Market - Segmentation by Geography
  • Figure 2.1 History of Precision Medicine
  • Figure 2.2 Key Areas of Application of Precision Medicine
  • Figure 2.3 Key Different Type of Data Used by Big Data Companies in Precision Medicine
  • Figure 2.4 Key Areas of Interest of Precision Medicine
  • Figure 4.1 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.2 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.3 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.4 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.5 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.6 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.7 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.8 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.9 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.10 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), 2018-2029
  • Figure 4.11 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), 2018-2029
  • Figure 5.1 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), 2018-2029
  • Figure 5.2 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), 2018-2029
  • Figure 6.1 Global Precision Cancer Diagnostic Tests National Market Share (%), 2018
  • Figure 6.2 Global Precision Cancer Diagnostic Tests National Market Share (%), 2029
  • Figure 6.3 US Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.4 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.5 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.6 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.7 Japanese Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.8 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.9 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.10 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.11 German Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.12 German Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.13 German Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.14 German Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.15 French Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.16 French Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.17 French Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.18 French Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.19 Italian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.20 Italian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.21 Italian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.22 Italian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.23 UK Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.24 UK Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.25 UK Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.26 UK Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.27 Spanish Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.28 Spanish Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.29 Spanish Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.30 Spanish Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.31 Chinese Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.32 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue, 2018-2029
  • Figure 6.33 Chinese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.34 Chinese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.35 Indian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.36 Indian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.37 Indian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.38 Indian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.39 Brazilian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.40 Brazilian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.41 Brazilian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.42 Brazilian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
  • Figure 6.43 Russian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
  • Figure 6.44 Russian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
  • Figure 6.45 Russian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
  • Figure 6.46 Russian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029

Companies Listed

  • Abbott Laboratories
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • Agios Pharmaceuticals, Inc.
  • Alere
  • Amgen
  • Amoy Diagnostics
  • Assurex
  • AstraZeneca
  • BeiGene
  • Biocartis N.V.
  • bioMérieux SA
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Cleveland Diagnostics, Inc.
  • Clinical Genomics
  • Clovis Oncology
  • Daiichi Sankyo
  • DAKO
  • DarwinHealth
  • Epic Sciences, Inc.
  • Five Prime Therapeutics, Inc.
  • Foundation Medicine
  • Genentech
  • Genomic Health, Inc.
  • GRAIL, Inc.
  • HealthWell Foundation
  • HeiScreen
  • Helix Holdings
  • Illumina, Inc.
  • Invivoscribe
  • Janssen Pharmaceuticals
  • Konica Minolta Precision Medicine Japan, Inc.
  • Lasergen, Inc.
  • Loxo Oncology
  • Medgenome
  • Merck Laboratories
  • Metafora Biosystems
  • Myriad Genetic Laboratories
  • Myriad Genetics, Inc.
  • NanoString Technologies
  • Natera
  • Novartis
  • Novogene Co.
  • Pfizer
  • PhoenixMD
  • Pierre Fabre
  • Qiagen, N.V.
  • Riken Genesis
  • Roche Holding AG
  • Siemens Healthineers
  • Spectrum Pharmaceuticals, Inc.
  • SRL, Inc.
  • St. Jude Medical
  • Strand Lifesciences
  • Takeda Pharmaceutical
  • Tarceva
  • Thermo Fisher Scientific, Inc.
  • Tianjin Novogene Bioinformatics Technology Company LTD
  • Xcode Lifesciences

List of Organizations Mentioned in the Report

  • American Lung Association
  • American Medical Association
  • American Society for Clinical Pathology
  • American Society of Clinical Oncology
  • Association for Molecular Pathology
  • Bpifrance
  • Centers for Medicare & Medicaid Services
  • Chinese National Medical Products Administration
  • College of American Pathologists
  • Columbia University Irving Medical Center
  • Columbia University Vagelos College of Physicians and Surgeons
  • European Medicines Agency
  • Health Innovation Manchester
  • Heidelberg University Women's Hospital
  • Japanese Pharmaceuticals and Medical Device Agency
  • Ministry of Health, Labor and Welfare
  • National Cancer Institute
  • National Coordinator for Health Information Technology
  • National Institutes of Health
  • Pharmaceutical and Medical Devices Agency
Back to Top